These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 38397999)
1. Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond. Soto A; Spongberg C; Martinino A; Giovinazzo F Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38397999 [TBL] [Abstract][Full Text] [Related]
2. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study. Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973 [TBL] [Abstract][Full Text] [Related]
3. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis. Burmeister Y; Weyer K; Dörre A; Seilheimer B Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437 [TBL] [Abstract][Full Text] [Related]
4. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Targher G; Byrne CD; Tilg H Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377 [TBL] [Abstract][Full Text] [Related]
5. Metabolic Muddle. MASLD and MASH on the Horizon. Meagher T J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924 [TBL] [Abstract][Full Text] [Related]
14. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus. Chen L World J Hepatol; 2023 Dec; 15(12):1253-1257. PubMed ID: 38223415 [TBL] [Abstract][Full Text] [Related]
15. Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Liu H; Yerevanian A; Westerhoff M; Hastings MH; Guerra JRB; Zhao M; Svensson KJ; Cai B; Soukas AA; Rosenzweig A Diabetes; 2024 Feb; 73(2):260-279. PubMed ID: 37934943 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma. Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077 [TBL] [Abstract][Full Text] [Related]
17. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study. Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759 [TBL] [Abstract][Full Text] [Related]
19. Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines. Pezzino S; Luca T; Castorina M; Puleo S; Latteri S; Castorina S Life (Basel); 2024 Jan; 14(1):. PubMed ID: 38255708 [TBL] [Abstract][Full Text] [Related]